title: Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
abstract: OBJECTIVE
  The aim of this study was to examine the therapeutic effects of an ethinyl estradiol (EE) and desogestrel (DSG) combination pill in polycystic ovary syndrome (PCOS).
  
  
  METHODS
  A total of 42 women with PCOS were treated with an EE 30 mcg and DSG 150 mcg (EE/DSG) combination pill for 12 cycles. The following parameters were studied at 0, 6, and 12months: body mass index, abdominal circumference, Ferriman-Gallwey score, presence of acne and acanthosis nigricans, serum testosterone and sex-hormone-binding globulin levels, fasting glucose and fasting insulin levels. Free androgen index and glucose:insulin ratio were calculated.
  
  
  RESULTS
  There were significant improvements in Ferriman-Gallwey score, incidence of acne, serum testosterone and sex-hormone-binding globulin levels and free androgen index values at the 6-month follow up. But there were no further beneficial changes in the above parameters at the 12-month follow up. There were no significant changes in body mass index, abdominal circumference, incidence of acanthosis nigricans, fasting glucose and insulin levels and glucose:insulin ratio during treatment.
  
  
  CONCLUSIONS
  Significant improvements in hyperandrogenic parameters were seen only in the first 6months of treatment with EE/DSG in PCOS. Further continuation with this pill did not produce any significant improvement. There were no adverse effects on insulin sensitivity.
authors: S.C. Das Memorial Medical and Research Center Department of Pharmacology, Calcutta Medical College KPC Medical College, Kolkata, India. drsudhindra54@gmail.com
authors: Sudhindra Mohan
authors: SM
authors: Bhattacharya
authors: Mainak
authors: M
authors: Ghosh
authors: Ranjan
authors: R
authors: Basu
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001823:Body Composition / Q000187:drug effects; D015992:Body Mass Index; D017135:Desogestrel / Q000494:pharmacology / Q000627:therapeutic use*; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007194:India; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000378:metabolism; D011372:Progestins / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D004967:Estrogens; D007328:Insulin; D011372:Progestins; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D004997:Ethinyl Estradiol; D017135:Desogestrel